Oligonucleotide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Synthesized Oligonucleotide Products, Reagents, Equipment, and Services), By Application (Research, Therapeutics, and Diagnostics), By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, and Hospital and Diagnostic Laboratories), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.77 Billion
CAGR (2026-2031)	13.62%
Fastest Growing Segment	Research
Largest Market	North America
Market Size (2031)	USD 10.26 Billion

Market Overview

The Global Oligonucleotide Synthesis Market is projected to grow from USD 4.77 Billion in 2025 to USD 10.26 Billion by 2031 at a 13.62% CAGR. Oligonucleotide synthesis entails the chemical fabrication of defined nucleic acid sequences used extensively in research, molecular diagnostics, and therapeutic development. The market is primarily driven by the increasing regulatory approval of nucleic acid-based medicines and the expanding application of these molecules in treating rare genetic disorders. According to the American Society of Gene & Cell Therapy, in 2025, 38 new trials were initiated in the RNA therapy pipeline during the second quarter alone, with 74% of these targeting non-oncology indications. This diversification of therapeutic targets demonstrates a robust demand for synthetic oligonucleotides beyond traditional cancer treatments.

Despite this momentum, a significant challenge impeding broader market expansion is the difficulty of achieving efficient intracellular delivery to tissues beyond the liver. The inherent negative charge and size of oligonucleotides restrict their bioavailability and cellular uptake, necessitating complex delivery vehicles or chemical modifications that increase development costs and technical hurdles for pharmaceutical manufacturers.

Key Market Drivers

Expanding Pharmaceutical and Biotechnology R&D Expenditure is a predominant driver accelerating the Global Oligonucleotide Synthesis Market. As the clinical success of RNA therapeutics grows, major pharmaceutical entities are directing substantial capital toward securing manufacturing self-sufficiency and expanding their nucleotide-based pipelines. This financial commitment is crucial for overcoming supply chain bottlenecks associated with complex chemical synthesis. According to BioPharma Dive, April 2025, in the 'Amid tariff turmoil, Novartis commits to spending $23B on US manufacturing' report, Novartis unveiled a strategic five-year plan involving a $23 billion investment to bolster its US production capabilities, which explicitly includes locating new antisense oligonucleotide drug manufacturing facilities in the region. Such large-scale expenditures underscore the industry's pivot from research-scale fabrication to commercial-volume synthesis to support maturing therapeutic portfolios.

Increasing Regulatory Approvals for Oligonucleotide-Based Drugs further catalyzes market expansion by validating the safety and efficacy of these molecules, thereby necessitating sustained commercial synthesis volumes. Each new approval transforms a candidate from a research project into a marketed product requiring consistent, high-purity manufacturing output. According to the Oligonucleotide Therapeutics Society, February 2025, in the '2024 FDA Approvals: A Wave of Innovation in Treating Serious Diseases' report, the regulatory landscape was significantly strengthened when the FDA approved Imetelstat (Rytelo) in June 2024, a first-in-class telomerase inhibitor for myelodysplastic syndromes. The confidence instilled by such regulatory milestones continues to fuel deal-making activity; for instance, according to AReNA, in 2025, Eli Lilly entered a strategic partnership with Creyon Bio valued at up to $1 billion to leverage artificial intelligence for designing novel oligonucleotide therapies.

Download Free Sample Report

Key Market Challenges

The difficulty of achieving efficient intracellular delivery to tissues beyond the liver constitutes a persistent restriction on the growth of the Global Oligonucleotide Synthesis Market. The large molecular size and negative charge of these sequences hinder their ability to penetrate cell membranes in organs such as the central nervous system, heart, and muscle, leading to poor bioavailability outside hepatic targets. This biological constraint forces developers to invest in expensive and complex delivery technologies, which prolongs development timelines and substantially elevates the capital required to bring non-liver therapeutics to market.

Consequently, the industry faces a commercial landscape that is heavily concentrated rather than diversified, as high attrition rates in extrahepatic programs limit the number of marketable end-products. This bottleneck effectively caps revenue streams and keeps the market dependent on a narrow set of successes. According to the Alliance for Regenerative Medicine, in 2025, 75% of the global revenue in the advanced therapy sector was generated by fewer than 10 products. This high degree of value concentration underscores how delivery hurdles directly impede the market's ability to translate emerging research into widespread commercial growth.

Key Market Trends

The commercialization of enzymatic DNA synthesis platforms is emerging as a critical trend, effectively addressing the limitations of traditional chemical phosphoramidite methods. This biological approach enables the production of longer, high-fidelity sequences without toxic by-products, thereby unlocking new applications in synthetic biology and precision medicine. The technology is rapidly maturing to handle increasingly complex genetic designs that were previously inaccessible. According to DNA Script, January 2025, in the 'DNA Script Breaks Length and Complexity Barriers With New Enzymatic DNA Synthesis Offering' announcement, the company launched a new enzymatic synthesis capability specifically engineered to produce challenging sequences, such as those with high GC content and complex secondary structures, which were difficult to manufacture using standard benchtop systems.

Concurrently, the market is witnessing a significant surge in outsourcing to Contract Manufacturing Organizations (CMOs), driven by the escalating structural complexity of therapeutic oligonucleotides. As drug developers navigate intricate modifications and stringent cGMP requirements, they are increasingly relying on specialized CDMOs rather than building internal infrastructure for every program. This shift is substantiated by the financial performance of leading contract manufacturers. According to Bachem, July 2025, in its 'Half-Year Report 2025', the company reported that revenue from its CMC Development division rose by nearly 37% to CHF 123.7 million, a growth trajectory explicitly attributed to the robust and expanding demand for complex peptide and oligonucleotide development projects.

Segmental Insights

Based on current market analysis, the Research segment is emerging as the fastest-growing application within the Global Oligonucleotide Synthesis Market. This rapid expansion is primarily driven by the intensifying focus on genomic studies and the widespread adoption of advanced technologies such as CRISPR-Cas9 gene editing and Next-Generation Sequencing. Additionally, substantial funding and grants from major institutions, including the National Institutes of Health, are significantly accelerating academic and pharmaceutical discovery projects. These factors collectively fuel a surge in demand for custom synthesized oligonucleotides, establishing the Research segment as a critical driver of future market development.

Regional Insights

North America maintains a leading position in the global oligonucleotide synthesis market, primarily driven by substantial investments in pharmaceutical research and development. The region benefits from a favorable regulatory environment, where the United States Food and Drug Administration actively supports the advancement of genomic medicines. Additionally, the presence of major biotechnology firms and a strong focus on personalized therapies for genetic disorders accelerate market expansion. This dominance is further sustained by established infrastructure and significant funding dedicated to life sciences, ensuring a stable commercial landscape for therapeutic innovation.

Recent Developments

• In January 2025, Sanofi and Alloy Therapeutics announced a research collaboration valued at up to $400 million to co-develop a novel antisense oligonucleotide (ASO) therapy for an undisclosed disease. The partnership leverages the biotechnology company’s proprietary AntiClassic Antisense platform, which is designed to overcome delivery challenges associated with traditional oligonucleotide therapies, particularly in crossing the blood-brain barrier. Under the agreement, the partners will combine their expertise in genetic medicine and drug development to advance the candidate through preclinical and clinical stages. This collaboration highlights the continued investment by major pharmaceutical companies in next-generation oligonucleotide technologies to treat complex neurological conditions.
• In July 2024, Agilent Technologies Inc. entered into a definitive agreement to acquire BioVectra, a specialized contract development and manufacturing organization based in Canada, for $925 million. This acquisition is intended to bolster the company's capabilities in the production of oligonucleotides and CRISPR therapeutics. By integrating the acquired entity's expertise in biologics, lipid nanoparticle formulation, and mRNA capabilities, the company aims to provide end-to-end biopharmaceutical solutions. The transaction expands the acquirer's service portfolio to include sterile fill-finish services and supports the manufacturing of fast-growing modalities like antibody-drug conjugates and highly potent active pharmaceutical ingredients.
• In May 2024, Twist Bioscience Corporation launched its Multiplexed Gene Fragments (MGFs), a new product designed to facilitate high-throughput screening applications for researchers. These gene fragments are directly synthesized as pools of double-stranded DNA with lengths of up to 500 base pairs and can include an unlimited number of sequences. The product utilizes the company's silicon-based DNA synthesis platform to enable complex applications such as CRISPR-based functional screening, antibody discovery, and protein engineering. This launch allows customers to obtain high-quality gene fragments in a pooled format, significantly improving efficiency and cost-effectiveness for large-scale genomic research workflows.
• In April 2024, Asahi Kasei Bioprocess and Axolabs announced a strategic partnership to construct a new current Good Manufacturing Practice (cGMP) oligonucleotide manufacturing facility in Berlin, Germany. The collaboration aims to address the rapidly escalating global demand for oligonucleotide therapeutics by establishing a state-of-the-art manufacturing hub that spans approximately 59,000 square feet. This facility will uniquely integrate the advanced synthesis equipment expertise of the Japanese conglomerate's subsidiary with the deep process development and commercial manufacturing capabilities of the German contract research organization. The site is explicitly designed to accelerate the development and commercialization of oligonucleotide-based therapies for various genetic disorders.

Key Market Players

• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc.
• Merck KGaA
• BIO-Synthesis Inc
• Eurofins Scientific SE
• Danaher Corporation
• Ajinomoto Co. Inc.
• Biogen Inc.
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.

By Product Type	By Application	By End User	By Region
Synthesized Oligonucleotide Products Reagents Equipment Services	Research Therapeutics Diagnostics	Academic Research Institutes Pharmaceutical and Biotechnology Companies Hospital Diagnostic Laboratories	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Oligonucleotide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Oligonucleotide Synthesis Market, By Product Type:

• Synthesized Oligonucleotide Products
• Reagents
• Equipment
• Services

• Oligonucleotide Synthesis Market, By Application:

• Research
• Therapeutics
• Diagnostics

• Oligonucleotide Synthesis Market, By End User:

• Academic Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospital
• Diagnostic Laboratories

• Oligonucleotide Synthesis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE